ProMIS Neurosciences 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Neil K. Warma

최고 경영자

US$40.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	6.7yrs

최근 관리 업데이트

Recent updates

CEO

Neil K. Warma (61 yo)

less than a year

테뉴어

US$40,000

보상

Mr. Neil K. Warma, MBA, serves as Chief Executive Officer and President of ProMIS Neurosciences, Inc. from August 1, 2024 and has been its Director since December 30, 2023 and was its Interim Chief Executi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 147.1k
Neil K. Warma	CEO, President & Director	less than a year	US$40.00k	데이터 없음
Neil Cashman	Co-Founder	20.5yrs	US$378.82k	0.57% $ 105.7k
Gavin Malenfant	Chief Operating Officer	3.1yrs	US$435.90k	0.013% $ 2.4k
Daniel Geffken	Chief Financial Officer	7.7yrs	US$142.40k	0.029% $ 5.4k
Johanne Kaplan	Chief Development Officer	8.3yrs	US$525.57k	0.024% $ 4.4k
David Wishart	Chief Physics Officer	3.5yrs	데이터 없음	데이터 없음
Dennis Chen	Head of Manufacturing & Senior Consultant	no data	데이터 없음	데이터 없음
Larry Altstiel	Chief Medical Officer	2.6yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: PMN 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 147.1k
Neil K. Warma	CEO, President & Director	3.5yrs	US$40.00k	데이터 없음
Neil Cashman	Co-Founder	17.8yrs	US$378.82k	0.57% $ 105.7k
William Wyman	Independent Director	10.7yrs	US$40.00k	0.31% $ 57.9k
William Mobley	Member of Scientific Advisory Board	7.4yrs	데이터 없음	데이터 없음
Patrick Kirwin	Independent Director	9.4yrs	US$40.00k	0.49% $ 91.2k
Joshua Mandel-Brehm	Independent Director	3.2yrs	US$40.00k	0% $ 0
Sharon Cohen	Member of Scientific Advisory Board	6.7yrs	데이터 없음	데이터 없음
Andre Strydom	Member of Scientific Advisory Board	5.3yrs	데이터 없음	데이터 없음
Michelle Hastings	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Madge Shafmaster	Lead Independent Director	3.2yrs	US$40.00k	1.04% $ 191.7k
Carsten Korth	Member of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음

6.7yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: PMN 의 이사회는 경험(평균 재직 기간 6.7 년)으로 간주됩니다.

ProMIS Neurosciences 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령